Rafael de Cabo
Dr. Rafael de Cabo is a senior researcher at the National Institute on Aging, with over two decades of experience studying the effects of metformin on aging in animal models. His work has explored the drug's potential to extend lifespan and its implications for treating age-related diseases, making him a key figure in the ongoing research into the intersection of diabetes management and longevity.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Switzerland | 1 | 6.00 | 0.08% | +0% | 8,654,622 | 7,025 | $700,000 | 568$ |
| Totals | 1 | 8,654,622 | 7,025 | $700,000 | 568$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Rafael de Cabo presented new data regarding Taurin's levels in the body as it relates to aging.
6
Spain:
Rafael de Cabo is the head of the Translational Gerontology Department at the National Institute on Aging in Baltimore, USA, and he leads a study questioning previous results on taurine and aging.
7
Turkey:
Dr. Rafael de Cabo's research showed that low doses of metformin extended the lifespan of healthy male mice by about 5%.
7
Liechtenstein:
Rafael de Cabo is a senior researcher studying metformin and its effects on aging at the National Institute on Aging.
6
Guatemala:
Rafael de Cabo is a senior researcher at the National Institute on Aging who has studied metformin in mice for over two decades.
6